Kymera Results Presentation Deck

● ● Interim Safety Data Summary Dose Levels 1-2 All patients with heavily pretreated B-cell lymphoma (up to 3 prior lines of therapy) Follicular lymphoma, DLBCL (all wild-type MYD88) No DLTS, no treatment-related SAES or AEs leading to discontinuation, no neutropenia in first two dose levels KYMERA ©2022 KYMERA THERAPEUTICS, INC. PAGE 19

View entire presentation